1. Early Referral for Patients With IBD Failing Conventional Therapies

2. Background

3. Questions

4. Red Flags Index for CD (IOIBD)

5. How Long Is the Delay?

6. Why Is Diagnosis Delayed?

7. Why Does Delay Matter?

8. If IBD Is Progressive, a Window of Opportunity May Exist: UC

9. If IBD Is Progressive, a Window of Opportunity May Exist: CD

10. Step Up vs Top Down: Early Combined Therapy Improves Outcomes

11. REACT: Study Results

12. REACT-2: Ongoing Study Using an Enhanced Treatment Algorithm

13. Early Intervention With Biologics Appears to Improve Outcomes

14. Clinical Practice: Expert Advice

15. CALM: Treatment Escalation Based on Clinical Symptoms Combined With Biomarkers (Tight Control) is Better vs Symptoms Alone (Clinical Management)

16. Clinical Practice: Expert Advice (Cont)

17. Clinical Practice: Expert Advice (Cont)

18. EXTEND: Early Use of Continuous Anti-TNF Therapy Improves Endoscopic Outcomes in CD

19. Early Use of Vedolizumab and Ustekinumab

20. US VICTORY Consortium for IBD: Cohort Study

21. LOVE-CD: Prospective Study Comparing Early vs Late Use of Vedolizumab in Patients With CD

22. Identifying Patients Who May Benefit From Early Use of Biologics

23. Managing the Individual Patient With IBD

24. Final Thoughts

25. Abbreviations